Avelo Appoints Highly Experienced Board of Directors
October 6, 2022. Avelo AG, a Swiss breath diagnostics company with a mission to make every breath count for better infectious disease...
Avelo closes CHF 2.2 million oversubscribed seed round
The funds will accelerate the clinical validation of the breath collector for non-invasive sampling of patients with Tuberculosis and...
Swiss Handelzeitung's Upbeat features Avelo
June 30, 2022. Learn more about Avelo and its CEO's entrepreneurial motivation here.
Avelo wins CHF 150'000 from VentureKick
June 29, 2022. Avelo wins CHF 150,000 from VentureKick to make every breath count for better respiratory disease diagnosis. The company...
Avelo and its partners receive Innosuisse grant for more efficient Tuberculosis diagnosis
June 15, 2022. Avelo, in collaboration with the research team at the Zurich University of Applied Sciences (ZHAW) and researchers from...
Avelo Appoints Scientific Advisory Board
January 15, 2021. Avelo Inc. welcomes four highly regarded experts in global health, infectious disease diagnostics development,...